AAPM&R Now Recommends PRP for Knee Osteoarthritis: What This Means for Patients

On April 16, 2026, the American Academy of Physical Medicine and Rehabilitation (AAPM&R) released a new clinical guidance statement. This organization is one of the largest physiatry groups in the United States. It represents about 10,000 physician members. The statement is about using platelet-rich plasma (PRP) for knee osteoarthritis. The recommendation is clear. PRP should be considered for patients with mild to moderate knee osteoarthritis (Kellgren-Lawrence grades I-III). These patients still have symptoms after good conservative management. This management includes physical therapy, NSAIDs, and activity modification.

This is not a small development. For years, PRP had an unclear place in musculoskeletal medicine. The data was promising, but no major medical society gave a formal endorsement. That has now changed. I am a physician who has used PRP in my practice for over a decade. I can tell you that this guidance represents a significant shift in the standard of care. It moves PRP from "promising but unproven" to "recommended by a major medical society." Some patients are told their only options are cortisone injections or waiting for a knee replacement. For them, this changes the conversation entirely.

What the AAPM&R Guidance Actually Says

The guidance statement was published in the PM&R journal. A multidisciplinary panel of experts developed it after a systematic review of the evidence. Their key recommendation is to offer PRP to patients with symptomatic knee osteoarthritis of Kellgren-Lawrence grades I, II, or III. These patients have not gotten enough relief from first-line conservative treatments. The panel specifically notes that PRP is not recommended for severe (grade IV) osteoarthritis. In those cases, joint space narrowing and bone-on-bone contact limit the potential for meaningful improvement.

This aligns precisely with how I evaluate patients in my practice. A patient comes to me with knee pain. Imaging shows mild to moderate degenerative changes. I perform a thorough biomechanical assessment first. This includes osteopathic manipulative treatment to address joint restrictions and muscle imbalances. I do this before considering any injection. If conservative measures have been exhausted and the patient still has symptoms, PRP is often the next logical step. For a detailed explanation of how PRP works, how it compares to cortisone, and how Kellgren-Lawrence grading guides treatment decisions, I recommend reading our detailed guide to PRP for knee osteoarthritis.

Why This Guidance Matters

Institutional validation matters in medicine. A society like AAPM&R issues a formal recommendation. This signals to insurers, referring physicians, and patients that the treatment has crossed a threshold of evidence and clinical acceptance. For PRP, this is a watershed moment.

Before this guidance, many patients were told by their orthopedists or primary care doctors that PRP was "experimental" or "not covered." Insurance coverage for PRP remains limited. This guidance alone will not change that overnight. But it provides a powerful tool for advocacy. A major medical society now says the treatment is recommended. This makes it much harder for payers to dismiss it as unproven. I expect we will see gradual movement toward coverage. This will be especially true for patients who meet the specific criteria outlined in the guidance.

Equally important, this guidance gives patients permission to ask for PRP. You may have been told "just wait for a replacement" or "cortisone is your only option." You now have a nationally recognized medical society backing an alternative. Cortisone injections can provide short-term relief. But repeated use may accelerate cartilage loss. PRP, by contrast, aims to modify the underlying disease process. It delivers concentrated growth factors to the joint. Multiple meta-analyses have consistently shown that PRP outperforms hyaluronic acid and corticosteroid injections. It provides sustained improvement in pain and function for knee osteoarthritis. The AAPM&R guidance reflects that evidence.

Not All PRP Is the Same

One of the most important points in the new guidance is about preparation quality. I emphasize this with every patient. PRP outcomes depend highly on it. A 2026 study by Hooper and colleagues was published in PM&R. It demonstrated that the total deliverable platelet dose is directly associated with clinical outcomes. In other words, more platelets and a more consistent platelet concentration lead to better results.

This is not a trivial detail. Many clinics use off-the-shelf kits or single-spin systems. These produce variable platelet yields. In my practice, I use a double-spin protocol. This allows me to control the concentration and volume of the injectate. I also combine PRP with a thorough biomechanical evaluation. An injection into a joint that is still under abnormal mechanical stress is less likely to succeed. That is why I always incorporate osteopathic manipulative treatment into the treatment plan. It addresses the underlying joint mechanics that contributed to the osteoarthritis in the first place.

When you read about PRP studies, it is critical to ask questions. What preparation system was used? What was the platelet count? Was leukocyte content controlled? The AAPM&R guidance acknowledges these variables. It calls for standardization in future research. For now, this means patients should seek out providers who are transparent about their preparation methods. They should also have experience with PRP for knee osteoarthritis.

What This Means If You Have Knee Osteoarthritis

You may be an active adult in your 30s or 40s with knee pain. This pain limits your ability to run, hike, or play sports. Or you may be over 50 and have been told to "learn to live with it." In either case, this guidance is directly relevant to you. The recommendation applies to patients with mild to moderate osteoarthritis. This is the vast majority of people who have knee OA. It does not apply to those with advanced bone-on-bone changes. But for everyone else, PRP is now a recommended option.

In my practice, I see realistic expectations as essential. For patients with Kellgren-Lawrence grades I-III, I typically see a 60-70% meaningful improvement in pain and function. Results can last 12 to 18 months or longer. PRP is not a cure. Osteoarthritis is a chronic condition. But it can delay the need for more invasive interventions like arthroscopy or joint replacement. PRP uses your own blood components. So the safety profile is excellent. There is minimal risk of allergic reaction or infection.

If you are considering PRP, the first step is a proper evaluation. This includes imaging to confirm the grade of osteoarthritis. It includes a physical exam to assess joint stability and alignment. And it includes a discussion of your activity goals. I also assess whether osteopathic manipulative treatment can address any biomechanical contributors to your knee pain. From there, we can determine whether PRP is appropriate for you.

For more information on how PRP is prepared, what the injection experience is like, and how it compares to other treatments, please see our comprehensive guide. If you have questions about whether you are a candidate, I encourage you to schedule a consultation.